Invetech, a global leader in advanced therapies and diagnostics manufacturing solutions, has announced a strategic collaboration with AiCella, an AI-driven biotech startup, to advance cell therapy innovation. This partnership combines Invetech’s expertise in end-to-end automation with AiCella’s predictive AI platform to deliver smarter, faster, and more cost-effective cell therapy production processes, enhancing patient outcomes.
Invetech and AiCella announce strategic collaboration for cell therapy innovation.
Partnership integrates Invetech’s automation expertise with AiCella’s AI platform.
Aims to optimize manufacturing, reduce variability, and enhance therapeutic efficacy.
AiCella’s Insights™ platform uncovers critical process-patient outcome relationships.
Both companies to showcase joint capabilities at Meeting on the Mesa 2025.
Targets $10B+ cell therapy market with scalable, data-driven solutions.
The collaboration between Invetech and AiCella addresses persistent challenges in cell therapy manufacturing, such as process variability and scalability. By integrating AiCella’s Insights™ platform, which leverages advanced machine learning to correlate process inputs with patient outcomes, with Invetech’s proven automation platforms, the partnership enables developers to identify critical parameters early, streamline workflows, and reduce costs. This approach accelerates the transition from clinical to commercial-scale manufacturing, ensuring consistent, high-quality therapies.
"This collaboration is about more than just combining technologies—it’s about solving some of the most persistent challenges in cell therapy production," said Andreas Knaack, President of Invetech. "By integrating AiCella’s predictive AI models with our proven technology platforms, we aim to help therapy developers identify critical process parameters earlier, reduce manufacturing variability, and ultimately accelerate the path to scalable, patient-ready therapies."
AiCella’s Insights™ platform revolutionizes cell therapy development by analyzing real-world process and clinical data to uncover hidden relationships that traditional methods often miss. This data-driven approach optimizes manufacturing efficiency and enhances therapeutic outcomes, supporting biopharma developers in the $10B+ cell therapy market. By embedding AI models into the manufacturing lifecycle, AiCella empowers developers to generate hypotheses that improve therapy personalization and efficacy.
"Our goal at AiCella is to uncover the hidden relationships between process inputs and patient outcomes—insights that traditional methods often miss," said Geoffrey Stephens, PhD, CEO and Founder of AiCella. "Through this collaboration with Invetech, we’re embedding our AI models directly into the development and manufacturing lifecycle. This allows us to not only optimize process performance but also to generate data-driven hypotheses about which parameters most influence therapeutic efficacy—bringing us closer to truly personalized, responsive cell therapies."
The partnership positions Invetech and AiCella to address the growing demand for scalable cell therapy solutions, particularly in personalized medicine like CAR-T therapies. With the global cell therapy technologies market projected to grow from USD 7.68 billion in 2025 to USD 17.46 billion by 2030 at a CAGR of 17.84%, this collaboration is well-timed to drive innovation in a rapidly expanding industry. Both companies will showcase their joint capabilities at industry events, including Meeting on the Mesa in October 2025, offering a platform to demonstrate their impact on cell therapy development.
Invetech’s three decades of experience in delivering GMP-compliant, automated manufacturing systems, combined with AiCella’s AI-driven insights, creates a powerful synergy. This collaboration is set to transform the cell therapy landscape by enabling faster, more efficient, and patient-centric therapy development, ultimately improving access to life-changing treatments worldwide.
Invetech is your trusted partner in solving complex End-to-End manufacturing and product development challenges in the global advanced therapies market. For more than three decades, we've partnered with leaders in diagnostics, life sciences, and cell therapy to co-create breakthrough solutions that transform ideas into market-ready technologies and therapies. Whether transitioning from early process development to commercial-scale manufacturing or optimizing complex workflows, our team combines scientific insight, engineering excellence and proven technology platforms to deliver tailored solutions. Our proven modules, technology platforms and custom automation solutions integrate seamlessly with your processes, reducing time to market, and supporting scalable, GMP-compliant manufacturing. Together with our clients, we're advancing healthcare.
AiCella is an AI-driven biotech startup transforming the $10B+ cell therapy manufacturing market. By integrating real-world process and clinical data with advanced machine learning models, AiCella's platform, Insights™, helps biopharma developers optimize manufacturing efficiency, reduce costs, and improve therapeutic outcomes. AiCella revolutionizes process development by seamlessly integrating real process and clinical data to maximize responses for patients. Using data collected with our world class, strategic partners, our Insights™ platform will enable researchers across the globe to bridge the gap between process development and clinical responses, unlocking unparalleled insights and accelerating the journey from innovation to impactful patient outcomes. Our dedication to leveraging unique datasets and groundbreaking technologies via the Insights™ platform drives us to shape the future of process development by empowering researchers to make unprecedented strides in improving human health.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.